Additional Information
Short Description: |
E3 Ubiquitin Ligase Inhibitor |
Research Area: |
Cancer, Cancer Growth Inhibitors, Angiogenesis Inhibitors, Cell Signaling, Post-translational Modifications, Ubiquitination, E3 Ubiquitin Ligases |
Alternative Name(s): |
1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide |
Category: |
Small Molecules |
Product Type: |
Inhibitor |
CAS No.: |
19171-19-8 |
Molecular Formula: |
C13H11N3O4 |
Molecular Weight: |
273,2 |
Source: |
Synthetic |
Purity: |
>98% (TLC); NMR (Conforms) |
Solubility: |
May be dissolved in DMSO (50 mg/ml) |
Appearance: |
Yellow powder |
Storage: |
-20ºC |
Shipping: |
Shipped Ambient |
SMILES: |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N |
InChI: |
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) |
InChIKey: |
UVSMNLNDYGZFPF-UHFFFAOYSA-N |
Field of Use: |
For in vitro research use only. |
Related Products
Pomalidomide | E1KS1567
426
$2,289.00
Pomalidomide | E1KS1567 | Gentaur UK, US & Europe Distribution
426-E1KS1567
Pomalidomide | B1811
26
$1,186.50 - $2,789.50
Pomalidomide is a derivative of Thalidomide (Cat. No. 2020) and a second-generation immunomodulatory drug. Pomalidomide targets the E3 ligase protein cereblon, preventing cereblon autoubiquitination...
26-B1811-GEN
